Each year in Catalonia, roughly 1,000 women die of breast cancer and 275 of ovarian cancer
Global experts in women’s cancer present latest advances in prevention, early diagnosis and therapies at B·Debate
2017
Best Ideas 2017” award to Manel Esteller
Last Monday, November 13th, the ‘Best Ideas 2017’ awards ceremony, organized annually by the Diario Médico newspaper, took place at the National Theater of Catalonia. In this year’s edition, Dr. Manel Esteller, Researcher of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Research Professor and Professor of Genetics of the University of Barcelona received one of
Best Ideas 2017” award to Manel Esteller Read More »
Ramon Salazar receives funding for a research project on colon cancer
The Spanish Association Against Cancer (AECC) and the Carlos III Health Institute (ISCII) have decided to financially contribute to the ‘Horizon 2020 TRASCAN’ program of the European Union to fund five Spanish projects TRASCAN Project
Ramon Salazar receives funding for a research project on colon cancer Read More »
The ‘Viladecans Against Cancer’ Association Coordinator raises 16.186 euros for stomach cancer research in IDIBELL
During the course of an open ‘paella’ that brought together seven hundred and fifty people in the Cúbic space of Viladecans, the Association Viladecans Against Cancer officially offered a 16,186 euros check to IDIBELL for the investigation of new therapies in the fight against stomach cancer, led by Dr. Núria Sala (IDIBELL-ICO). This amount brings
Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy
Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment. Collaboration between research and industry led to the identification and successful testing of a new molecule capable of preventing this neurological complication. This molecule could potentially become the first existing treatment to prevent this frequent adverse effect and improve the quality of life of cancer patients. Article citation
Researchers identify neural mechanisms that strengthen or weaken memories during sleep
Technique to reactivate memories Network reactivated memories Differences in electrophysiological activity
Researchers identify neural mechanisms that strengthen or weaken memories during sleep Read More »
A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer
Researchers from the Hereditary Cancer group of the Oncobell Program of the Bellvitge Biomedical Research Institute (IDIBELL) – Hereditary Cancer Program of the Catalan Institute of Oncology (ICO) have found a new genetic marker that would explain up to 1.4% of those inherited colon cancer cases not related to the mutations currently associated with this
A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer Read More »
IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients
The tumoral microenvironment subverts immune cell function A key regulator of myeloid derived suppressor cells and the possibility of reverting its effects on immune fucntion Article citation
El Campus de Bellvitge acoge la exposición ‘María Sklodowska-Curie, una polaca en París’
Una muestra para reivindicar la figura de Marie Curie María Sklodowska-Curie
El Campus de Bellvitge acoge la exposición ‘María Sklodowska-Curie, una polaca en París’ Read More »
Success of the “H2020 Opportunities” informative session
On September 21st, an “Oportunidades en H2020 SC1 2018-20” workshop was held in the Pau Viladiu hall of Duran i Reynals Hospital. This session was jointly organized by IDIBELL’s Research Support Office and ICO’s Research Management Unit on the occasion of the imminent opening of calls for the Work Program of the H2020 Social Challenge
Success of the “H2020 Opportunities” informative session Read More »